Dihydromyricetin

Dihydromyricetin is a potent inhibitor with an IC50 of 48 μM on dihydropyrimidinase. Dihydromyricetin can activate autophagy through inhibiting mTOR signaling. Dihydromyricetin suppresses the formation of mTOR complexes (mTORC1/2) . Dihydromyricetin is also a potent influenza RNA-dependent RNA polymerase inhibitor with an IC50 of 22 μM.

Product Specifications

CAS Number

[27200-12-0]

Product Name Alternative

Ampelopsin; Ampeloptin

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; DNA/RNA Synthesis; Influenza Virus; mTOR

Type

Natural Products

Related Pathways

Anti-infection; Autophagy; Cell Cycle/DNA Damage; PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Infection

Assay Protocol

https://www.medchemexpress.com/Dihydromyricetin.html

Concentration

10mM

Purity

99.73

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C1[C@H](O)[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13

Molecular Formula

C15H12O8

Molecular Weight

320.25

Precautions

H302, H315, H319, H335

References & Citations

[1]Huang CY. Inhibition of a Putative Dihydropyrimidinase from Pseudomonas aeruginosa PAO1 by Flavonoids and Substrates of Cyclic Amidohydrolases. PLoS One. 2015 May 19;10 (5) :e0127634.|[2]Kou X, et al. Ampelopsin attenuates brain aging of D-gal-induced rats through miR-34a-mediated SIRT1/mTORsignal pathway. Oncotarget. 2016 Nov 15;7 (46) :74484-74495.|[3]Chang H, et al. Ampelopsin suppresses breast carcinogenesis by inhibiting the mTOR signalling pathway. Carcinogenesis. 2014 Aug;35 (8) :1847-54.|[4]Václav Zima, et al. Unraveling the Anti-Influenza Effect of Flavonoids: Experimental Validation of Luteolin and its Congeners as Potent Influenza Endonuclease Inhibitors. Eur J Med Chem. 22 August 2020, 112754.